Literature DB >> 26081309

Psychiatric and cognitive symptoms in Huntington's disease are modified by polymorphisms in catecholamine regulating enzyme genes.

T Vinther-Jensen1,2, T T Nielsen1,3, E Budtz-Jørgensen4, I U Larsen1,5, M M Hansen2, L Hasholt2, L E Hjermind1,2, J E Nielsen1,2,3, A Nørremølle2.   

Abstract

Huntington's disease (HD) is an autosomal dominantly inherited neurodegenerative disorder characterized by motor, psychiatric, and cognitive manifestations. HD is caused by a CAG repeat expansion in the Huntingtin (HTT) gene but the exact pathogenesis remains unknown. Dopamine imbalance has previously been shown in HD, and furthermore dopamine is thought to be implicated in cognition, behavioral and motor disturbances. A substantiated inverse correlation between motor onset and the elongated CAG repeat in the HTT has been established. This relation does not account for the full variability of the motor onset, and efforts have been put into finding genetic modifiers of motor onset, however, mostly with unsuccessful outcome. In this study, we took an alternative approach focusing on symptom complexes and searched for modifiers of cognitive impairment and psychiatric symptoms in a well-described cohort of Danish HD gene-expansion carriers. We show that cognitive impairment and psychiatric symptoms in HD are modified by polymorphisms in the monoamine oxidase A (MAOA) and catechol-O-methyltransferase (COMT) genes and by the 4p16.3 B haplotype. These results support the theory of dopamine imbalance in HD, and point toward more personalized treatment modalities of HD in the future.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Huntington's disease; catecholamines; cognitive impairment; genetic modifiers; psychiatric symptoms

Mesh:

Substances:

Year:  2015        PMID: 26081309     DOI: 10.1111/cge.12628

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  6 in total

Review 1.  Glial evolution as a determinant of human behavior and its disorders.

Authors:  Steven A Goldman
Journal:  Ann N Y Acad Sci       Date:  2020-05-25       Impact factor: 5.691

2.  Social Cognition, Executive Functions and Self-Report of Psychological Distress in Huntington's Disease.

Authors:  Ida Unmack Larsen; Tua Vinther-Jensen; Jørgen Erik Nielsen; Anders Gade; Asmus Vogel
Journal:  PLoS Curr       Date:  2016-12-28

3.  Huntingtin Is Required for Neural But Not Cardiac/Pancreatic Progenitor Differentiation of Mouse Embryonic Stem Cells In vitro.

Authors:  Man Shan Yu; Naoko Tanese
Journal:  Front Cell Neurosci       Date:  2017-02-21       Impact factor: 5.505

Review 4.  A Comprehensive Review on Beneficial Effects of Catechins on Secondary Mitochondrial Diseases.

Authors:  Baoyi Chen; Wenting Zhang; Chuyuan Lin; Lingyun Zhang
Journal:  Int J Mol Sci       Date:  2022-09-30       Impact factor: 6.208

5.  COMT Val158Met Polymorphism Modulates Huntington's Disease Progression.

Authors:  Ruth de Diego-Balaguer; Catherine Schramm; Isabelle Rebeix; Emmanuel Dupoux; Alexandra Durr; Alexis Brice; Perrine Charles; Laurent Cleret de Langavant; Katia Youssov; Christophe Verny; Vincent Damotte; Jean-Philippe Azulay; Cyril Goizet; Clémence Simonin; Christine Tranchant; Patrick Maison; Amandine Rialland; David Schmitz; Charlotte Jacquemot; Bertrand Fontaine; Anne-Catherine Bachoud-Lévi
Journal:  PLoS One       Date:  2016-09-22       Impact factor: 3.240

6.  Disease-modifying effects of ganglioside GM1 in Huntington's disease models.

Authors:  Melanie Alpaugh; Danny Galleguillos; Juan Forero; Luis Carlos Morales; Sebastian W Lackey; Preeti Kar; Alba Di Pardo; Andrew Holt; Bradley J Kerr; Kathryn G Todd; Glen B Baker; Karim Fouad; Simonetta Sipione
Journal:  EMBO Mol Med       Date:  2017-11       Impact factor: 12.137

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.